Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Lists
Only you see this
Abstract
In comparison with TACE plus donafenib, TACE plus donafenib with ICIs could significantly improve DCR, PFS, and OS as a potential first-line treatment for unresectable HCC with an acceptable safety profile.
BibTeX
@article{deng2024efficacy,
author = {Liwei Deng and Yan-Yuan Sun and Haiqing Wang and Changli Liao and Deshan Li and Guohui Xu and Xuegang Yang},
title = {{Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis}},
journal = {Journal of Hepatocellular Carcinoma},
year = {2024},
doi = {10.2147/jhc.s443779},
}Loading related content...